In May 2024, the Company entered into an exclusive license agreement (the Joyo License Agreement) with Guangzhou Joyo Pharmatech Co., Ltd. (Joyo) under which the Company was granted an exclusive, wor…
In May 2024, the Company entered into an exclusive license agreement (the Medshine License Agreement) with Medshine Discovery Inc. (Medshine) under which the Company was granted an exclusive, worldwi…
the Company’s ability to successfully defend against allegations raised by, or any future litigation initiated by, Revolution Medicines (RevMed) that ERAS-0015 infringes patents held by RevMed
Reciprocal relationship from RVMD graph: Reciprocal relationship from ERAS graph: Reciprocal relationship from RVMD graph: Reciprocal relationship from ERAS graph: the Company’s ability to successful…
Erasca, Inc. Customers
No clients on recordNo downstream customers found in our database for Erasca, Inc..
Erasca, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
ERAS-DEBT
Debt stack $46.0M
90%
Market cache reports total debt of $46.0M.
ERAS-DEBT-9347
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2021-12-31.
Erasca, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Erasca, Inc..
Erasca, Inc. Ownership
Holder
Name
Confidence
Evidence
ERAS-OWNER-FRAZIER-LIFE-SCIENCES-MANAGEMENT
Frazier Life Sciences Management, L.P.
90%
13F overlay lists Frazier Life Sciences Management, L.P. as top holder; 226 tracked holders.
